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1014-67 Long-Term Outcome in Patients With Latent 
(Provocable) Obstructive Hypertrophic Cardiomyopathy 
Maria J. Eriksson Anna Woo, E. Douglas Wigle, David Focsaneanu, Paul Rakowski, 
Cairrine Sloggett, Harry Rakowski, Toronto General Hospital, Toronto, ON, Canada 
BACKGROUND: Subaortic obstruction in hypsrtrophic cardiomyopathy (HCM) may be 
classified as obstruction at rest or latent (LO). There is only limited information on long- 
term clinical outcome in HCM patients (pts) presenting with LO. 
METHODS: A retrospective study of 127 pts (73% male) with LOHCM was performed. 
Inclusion criteria were: unexplained left ventricular hypertrophy with no outflow gradient 
(LVOTGR) at rest and ~30 mmHg after provocation, documented by echo (n = 72) or 
catheterization (n = 55). Symptoms, clinical findings, mortality and cardiovascular mar- 
bidity were analyzed. 
RESULTS: The mean age at diagnosis was 45.1 * 15.6 years. At baseline the mean 
LVOTGR at rest was 7+6 mmHg and 64&6 mmHg after provocation. The mean septal 
thickness was 16.5k3.9 mm, with hypertrophy limited to the basal l/3 of septum in 74 pts 
(56%), and to the proximal 2/3 in 37 pts (29%). The mean left atrial diameter was 40*6 
mm. Most common symptoms were dyspnea (33%), chest pain (26%) and pre-lsyncope 
(15%). During a follow-up of 12.6&3 years from diagnosis cardiovascular mortality was 
5.5% (7027) and annual cardiovascular mortality 0.4%, due to sudden cardiac death 
(SCD) (n=4), CHF (n=2) and stroke (n=l). SCD pts had more extensive septal hypertro- 
phy. At 15 years of follow-up survival for LOHCM of 86+4% was not different from that for 
the age- and gender-matched population. Morbid events occurred in 59 pts (46%), the 
most frequent being atrial fibrillation (28%), cerebrovascular events (12%), myocardial 
infarction (9%) and CHF (9%). At the last follow-up pts were on beta-blockers (76%). dis- 
opyramide (19%) or/and calcium channel blockers (19%). Surgical or chemical myec- 
tomy was performed in 14 pts (11%). Seven pts received AICD, for secondary prevention 
(1) and primary prevention (6). Only left atrial enlargement at baseline and older age at 
diagnosis were independent predictors of cardiovascular morbidity. 
CONCLUSION: The majority of pts with LOHCM have less extensive hypertrophy and a 
more favorable prognosis than other types of HCM. However, in the presence of exten- 
sive hypertrophy, left atrial enlargement and older age at diagnosis, LO doss have signif- 
icant cardiovascular morbidity and mortality. 
1014-82 Relation Between Angiotensin-Converting Enzyme II 
Genotype and Cardiovascular Events in Patients With 
Hypettrophic Cardiomyopathy 
Akivoshi Ooimoto, Mareomi Hamada, Jun Nakura, Yuji Shigematsu. Yuji Ham, Tomoaki 
Ohtsuka, Jun Suzuki, Tsuyoshi Matsunaka, Tetsuro Miki, Jitsuo Higaki, Ehime University 
School of Medicine, Ehime, Japan 
Background: The renin-angiotensin system plays a part in the pathophysiology of cardio- 
vascular disease. Many studies showed the benefits of angiotensin converting enzyme 
(ACE) inhibitors in congestive heart failure. However, ACE inhibition in patients with 
hypertrophic cardiomyopathy (HCM) was reported to aggravate hemodynamics and lead 
to hypotension and excessive systolic emptying. The insertion/deletion (I/D) polymor- 
phism of the ACE gene is a marker linked to differences in plasma and cardiac ACE 
activity and an independent risk factor for several heart diseases. Therefore, the purpose 
of this study was to examine the relation between the ACE genotypes and the occur- 
rence of cardiovascular events in patients with HCM. Methods and Results: We geno- 
typed the I/D polymorphism of the ACE gene in genetically independent 151 patients with 
HCM. The cardiovascular events were defined as sudden cardiac death, congestive 
heart failure, thromboembolism. stroke, syncope. atrial fibrillation and sustained ventricu- 
lar tachycardia. Patients with one or more history of the cardiovascular events were 65 
(43%), and patients without history of the cardiovascular events were 66 (57%). Distribu- 
tion of the ACE oenotvoes (DD. ID. and II\ amona the total oatients with HCM was 14%. _ _. _ 
46%. and 40%, respectively. The cardiovascular events were documented in 36% with 
DD. 32% with ID. and 58% with II. Allele freauencv for the I allele was 0.71 in the orouo 
1  ” 
with the cardiovascular events and 0.56 in the other group. There was a significant differ- 
ence in genotypes between the two groups by chi-square test (PcO.01). The odds of the 
cardiovascular events was 3.1.fold higher in patients with the II genotype than in the 
other genotypes. Conclusion: These findings suggest that the II genotype of the ACE 
gene IS a significant risk factor for the cardiovascular events in patients with HCM. 
1014-83 Reduction in Mitral Regurgitation After Alcohol Septal 
Ablation in Patients With Hypertrophic Obstructive 
Cardiomyopathy 
Fred A. Crawford. Ill, Christopher Nielsen, Valerian Fernandes, Mary Frankis, Willlam H. 
Spencer, Ill, Medical University of South Carolina, Charleston, SC 
Background: Mitral Regurgitation (MR) is a common finding in patients with hyper- 
trophic obstructive cardiomyopathy (HOCM). This is thought to be related to systolic 
anterior motion of the mitral valve. Improvements in MR have been documented in paral- 
lel with reduction in left ventricular outflow tract (LVOT) gradient with both dual chamber 
pacing and with surgical myectomy. In this study, we examined reduction in MR and 
associated changes in LVOT gradient and treadmill exercise time before and after alco- 
hol septal ablation. Methods: We reviewed transthoracic echocardiograms from 40 
patients who underwent alcohol septal ablations periormed at our institution. Echocardio- 
grams were done before the procedure and in follow-up 3 months after the procedure. In 
addition to measuring LVOT gradient and treadmill exercrse time, we assessed degree of 
MR by measuring the area of color flow regurgitant jet, ratio of color flow regurgitant jet 
ares to left atrial area, and the peak mitral inflow E velocity. 
Results: At baseline, 39 of 40 patients had MR as measured by color flow doppler. 
There was a significant reduction in MR measured by transthoracic echocardiography at 
3 months follow-up. The pre-procedure mean mitral regurgitant jet area was 5.0 cm2. 
This decreased to 2.1 cm2 at 3 months follow-up (pcO.001). The pre-procedure mean 
mitral regurgitant jet area/ left atrial area was 0.36. This decreased to 0.20 at 3 months 
follow-up (p<O.OOl). The pre-procedure mean peak mitral inflow E velocity was 0.67 m/s. 
This decreased to 0.79 m/s at 3 months follow-up (~~0.05). The pre-procedure mean 
LVOT gradient was 65.6 mm Hg. This decreased to 26.3 mm Hg at 3 months follow-up 
(p<O.OOl). The pre-procedure mean treadmill exercise time was 233.1 seconds. This 
increased to 361.0 seconds at 3 months follow-up (p<O.OOl). Conclusions: Alcohol sep- 
tal ablation results in improved LVOT gradient and treadmill exercise time in patients with 
HOCM. This is associated with a significant reduction in MR. The reduction in MR may 
be an independent contributing factor to the improvement in exercise time and symptoms 
noted in these patients. 
1014-84 Noninvasive Assessment of Coronary Flow Velocity 
Reserve Impairment in Patients With Hypertrophic 
Cardiomyopathy 
Massimo Ruscazio, Roberta Montisci, Maurizio Porcu, Rosa Manzi, Luisella Pistis, 
Norma Zedda, Sabino Iliceto, Luigi Meloni, University of Cagliari, Cagliari, Italy, 
University of Padua, Padua, Italy 
Background.Microvascular impairment occurs frequently in hyperlrophic cardiomyopathy 
patients (HCM), often without evidence of coronary artery stenosis but with impairment of 
coronary flow velocity reserve (CFVR). We tested the hypothesis that CFVR, noninvasive 
monitored, can be impaired in HCM and could be related to the severity of cardiac hyper- 
trophy. 
Methods. We studied 16 HCM (13 males and 5 females), mean age 51 years (range 
16*72 years) and 21 control group patients. We evaluated CFVR in the left anterior 
descending coronary artery (LAD) with contrast enhanced transthoracic Doppler (CE- 
TTE) during adenosine infusion. The pulsed wave Doppler of blood flow velocity was 
recorded in the LAD at rest and after maximum vasodilation by adenosine infusion 
(140[mu]g/KgJmin in 5 minutes). 
Results. In HCM, CFVR was impaired compared to control group (2.3*0.66 Versus 
3.29eO.53 , pcO.001). A significantly, greater percentage of HCM had severe reduction of 
CFVR (~2.0) compared to control group (E/16,44% Versus O/21,0%, p=O.OOl). Diastolic 
mean velocity at rest was significantly higher in HCM with reduced CFVR compared both 
to control group (56.5t16.5 Versus 32.6i15.5 cm/set, pcO.01) and to HCM with normal 
CFVR (56.5+16.5 Versus 31.9i6.5 cm/set, p<O.Ol). However, diastolic mean velocity 
during hyperemia was not statistically different between the 2 groups (92526 Versus 
102+30 cmisec, p=ns) but in HCM with reduced CFVR it was statistically lower when 
compared to both control group (76.2e22.5 Versus 102+30.4 cmisec, ~~0.05 ) and HCM 
with normal CFR (76.2i22.5 Versus 104.5e30.4, ~~0.05 ).Furthermore, HCM with 
greater cardiac hypertrophy (>20 mm) had CFVR severely reduced in comparison to 
HCM with less degree of myocardial involvement (2.0*0.6 Versus 2.6i0.6, pcO.05). 
Conclusion. This study demonstrated that in HCM. CFVR is significantly impaired 
because of increased baseline resting diastolic mean velocity resulting in a reduced 
vasodilatatory capacity and CFVR impawment is related to the degree of cardiac hyper- 
trophy. Noninvasive CEE-TTE assessment of CFVR, could be a simple and reliable 
method in detecting and monitoring microcirculatory dysfunction in HCM. 
1014-85 Injury Size and Location induced by Percutaneous 
Transluminal Septal Myocardial Ablation in 
liypertrophic Obstructive Cardiomyopathy: Effect on 
Gradient Reduction 
Willem G. van Dockum, Folkeri J. ten Gate, Jurrien M. ten Berg, Aernout M. Beek, 
Jeroen Vos. Mark B. Hofman. Cees A. Visser. Alberl C. van Rossum, VU Universitv 
Medical Center, Amsterdam, The Netherlands 
Background: Percutaneous transluminal septal myocardial ablation (PTSMA) reduces 
left ventricular outflow tract (LVOT) obstruction in patients with symptomatic hypertrophic 
obstructive cardiomyopathy (HOCM). The purpose of the study was to evaluate by con- 
trast-enhanced magnetic resonance imaging (MRI) the effect of myocardial injury size 
and location induced by PTSMA on LVOT gradient reduction. 
Methods: Twenty-four patients (age 52+ 15 years) underwent contrast-enhanced (gado- 
linium-DTPA) MRI 1 month after PTSMA for assessment of PTSMA Induced myocardial 
injury size. Location of hyperenhanced myocardium was compared with ethanol infused 
target septal branch, site of balloon inflation and the volume of alcohol administered. 
